Amyloid-related imaging abnormalities

ARIA stands for Amyloid Related Imaging Abnormalities, changes seen on brain MRI in patients undergoing Alzheimer’s therapies. ARIA includes ARIA-E (edema or swelling) and ARIA-H (microhemorrhages and superficial siderosis). Detecting ARIA is essential to monitor patient safety and therapy response, and icobrain AI enables automated detection and quantification.

ARIA-E refers to fluid accumulation or edema, while ARIA-H involves small areas of bleeding visible on MRI. Both can indicate therapy-related effects and need careful monitoring to guide treatment decisions.

icobrain aria uses artificial intelligence (AI) algorithms on MRI sequences (FLAIR for ARIA-E, SWI/T2* for ARIA-H) to automatically identify, quantify, and track abnormalities. This provides objective data for clinicians and reduces variability compared to manual readings.

Yes. icobrain provides robust longitudinal tracking, allowing clinicians to monitor changes in ARIA lesions across multiple MRI scans, helping assess therapy impact and adjust patient management safely.

Automated ARIA detection informs decisions such as therapy continuation, dose adjustments, or additional monitoring. Clinicians get accurate, objective measurements that improve patient safety and treatment outcomes.

ARIA-E is detected on T2-weighted FLAIR sequences, while ARIA-H is best seen on susceptibility-weighted (SWI) or T2-weighted sequences*. icobrain aria analyzes these sequences automatically to highlight lesions for clinicians.

icobrain aria has high agreement with expert radiologists, providing reproducible lesion volumes and locations. This helps reduce human error and ensures consistent monitoring over time.

Yes. ARIA reports can be integrated into PACS or EMR systems using the icobridge, so clinicians can access AI findings directly within their existing workflow, improving efficiency and patient care.

Automated monitoring ensures early detection of abnormalities, reduces variability, and provides quantitative metrics that support safe and effective treatment decisions, making therapy management more precise.

AI solutions like icobrain aria provides quantitative, consistent, and automated monitoring of ARIA lesions over time. This reduces variability between radiologists, allows earlier detection of therapy-related changes, and supports safer treatment decisions.

icobrain analyzes MRI sequences with advanced algorithms, detecting subtle ARIA-E and ARIA-H changes that may not be visible in standard readings. This helps clinicians intervene earlier if adverse effects occur.

Yes. icobrain is vendor-agnostic, and can process MRI scans from all major MRI manufacturers of 1.5T and 3T field strength, ensuring consistent ARIA analysis across sites.